• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

'Central Nervous System Alzheimer Disease' Contains Detailed Information on the Current Drug Pipeline

Posted on: Tuesday, 29 April 2008, 09:01 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c90253) has announced the addition of "Central Nervous System Alzheimer Disease" to their offering.

"Central Nervous System Alzheimer Disease" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

- Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.

- Keep track of your competitors and partners by better understanding their product pipeline.

- Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.

- Maintain a critical competitive advantage.

--Top Companies in late stage Alzheimer Disease Projects

--Barr Pharmaceuticals Inc

--Asubio Pharma Co., Ltd.

--Cortex Pharmaceuticals Inc

--Baxter International Inc

--Debiopharm Group

--DAIICHI SANKYO COMPANY, LIMITED

--Eli Lilly & Co

--Elan Corp Plc

--Forest Laboratories Inc

--ExonHit Therapeutics SA

--Hunter-Fleming Ltd

--GlaxoSmithKline plc

--Pfizer Inc

--Ono Pharmaceutical Co., Ltd.

--Sanofi-Aventis

--Ranbaxy Laboratories Ltd.

--TOYAMA CHEMICAL CO.,LTD.

--Teva Pharmaceutical Industries Ltd

--Wyeth

--TransTech Pharma, Inc.

--Top Companies in early stage Alzheimer Disease Projects

--Chiesi Farmaceutici S.p.A

--AstraZeneca Plc

--Elan Corp Plc

--D-Pharm Ltd

--ExonHit Therapeutics SA

--Evotec AG

--Mediolanum farmaceutici S.p.A.

--Intellect Neurosciences, Inc.

--Merck & Co Inc

--Memory Pharmaceuticals Corp

--Neuropharma, S.A.

--Mindset BioPharmaceuticals Ltd.

--Pfizer Inc

--Nymox Pharmaceutical Corporation

--Samaritan Pharmaceuticals Inc

--Roche Holdings Ltd

--TorreyPines Therapeutics, Inc.

--Sanofi-Aventis

--Wyeth

--TransTech Pharma, Inc.

For more information, visit http://www.researchandmarkets.com/reports/c90253

Source: Life Science Analytics

Source: Business Wire

More News in this Category